-+ 0.00%
-+ 0.00%
-+ 0.00%

Biophytis Launches Joint Venture Operations in China

PUBT·11/09/2026 16:36:25
Listen to the news
Biophytis Launches Joint Venture Operations in China
  • Biophytis launched operations for its China joint venture on November 9, 2026, through its Shenzhen subsidiary.
  • A dedicated team will prepare the Chinese launch of SARA-31, an international Phase 3 study evaluating BIO101 in sarcopenia.
  • The next step is submitting a pre-IND dossier for the Phase 3 protocol to China's National Medical Products Administration.
  • Hong Kong authorities' approval of the venture's legal framework will enable signing of the final licensing and intellectual property contribution agreement.
  • Signing will pave the way for an initial $3 million financing tranche, within a commitment of up to $20 million over three years.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biophytis SA published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-124303), on November 09, 2026, and is solely responsible for the information contained therein.